MLKL and cancer: On the other hand, two iridium complexes were synthesized as necroptosis inducers in cisplatin-resistant cancer cells, such as complex 20, which can selectively accumulate in mitochondria, disrupt the mitochondrial membrane potential, and circumvent drug resistance, leading to the activation of receptor-interacting serine-threonine kinase 3 (RIPK3) and mixed lineage kinase domain-like pseudokinase (MLKL) [106].